Supporters

Gratitude

The Clinical Psychedelic Research Lab is incredibly grateful for the wonderful support from our partners and funders:

Support our research

Our plans for future research are directed towards:

  1. Expanding psychedelic research and treatment into new indications
  2. Exploring synergies between psychedelics and various psychotherapeutic and behavioural interventions
  3. Investigating therapeutic mechanisms
  4. Predicting patient response
  5. Improving sustained clinical benefits
  6. Developing translational models of care

The following projects are in planning and currently fundable. Please contact psychedelic@monash.edu if you would like to discuss supporting our work.

Response prediction for psychedelic-assisted therapy

The clinical benefits of psychedelics appear to depend in large part on the nature of the acute subjective experience (in addition to adequate preparation and extensive integration thereafter). This study will investigate whether certain acute drug experiences are predicted by pharmacogenomic, microbiomic, biomarker, and other individual differences in healthy volunteers.

Relapse prevention, tailored dosing, and long-term treatment effects

All psychedelic studies in the modern era have used brief and standardised interventions. This study will be the first to assess the safety and efficacy of long-term and highly tailored psilocybin-assisted psychotherapy treatment, varying the number and amount of drug doses, the amount of psychotherapy, and other parameters. In addition, a relapse prevention treatment model will be investigated.

Psycholytic psychotherapy

Moderate doses of psychedelics alongside more active forms of specialised psychotherapy (‘psycholytic psychotherapy’) were explored during the 1950s and 1960s, with some impressive reports. However, in the modern era, all clinical psychedelic studies have used high doses alongside a non-directive approach to the dosing session. This study will develop and investigate a novel approach to psycholytic therapy using psilocybin.

Synergies of psilocybin and meditation

Studies suggest that combined psychedelic-assisted therapy and meditation practices can enhance the beneficial effects of each intervention. This project will investigate how forms of meditation before, during and after psilocybin administration might enhance therapeutic effects in the treatment of mental ill-health.

Psychedelics and lifestyle changes

Psychedelics can greatly increase motivation to change problematic behaviour. This study will combine a short psychedelic intervention with best-practice in Lifestyle Medicine towards sustained long-term benefits.

Psilocybin for elite athlete mental health

Pressure to perform, overtraining, poor performance, interpersonal conflict, injury, and retirement at a young age all contribute to poorer mental ill-health in athletes than in the general population. This study will investigate the utility of psilocybin-assisted therapy specifically developed for elite athletes, and assess possible benefits to both mental health and athletic performance (to ascertain the possibility of sports ‘doping’).

Peer support forums

Establishing a free, clinically-moderated peer support forum (including an app) for people who have received psychedelic-assisted therapy within a clinical context would provide a form of continued care to individuals who have participated in psychedelic therapy trials and compassionate access. Such a forum may assist participants to better sustain the changes that occurred following psychedelic treatment and build community. Moreover, the long-term effects and implications of psychedelic treatments could be assessed, informing a more sustainable best-practice in treatment and continued care models.

Please contact psychedelic@monash.edu if you wish to discuss supporting our work, whether financially or otherwise!